Distribuzione geografica
Continente #
NA - Nord America 766
EU - Europa 465
AS - Asia 141
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 1375
Nazione #
US - Stati Uniti d'America 753
IT - Italia 336
CN - Cina 110
IE - Irlanda 38
DE - Germania 22
FI - Finlandia 21
VN - Vietnam 16
FR - Francia 14
CA - Canada 11
SE - Svezia 11
GB - Regno Unito 9
IN - India 9
IR - Iran 5
UA - Ucraina 4
BE - Belgio 3
BZ - Belize 2
BG - Bulgaria 1
CL - Cile 1
CZ - Repubblica Ceca 1
EG - Egitto 1
ES - Italia 1
EU - Europa 1
GR - Grecia 1
JP - Giappone 1
PL - Polonia 1
RS - Serbia 1
RU - Federazione Russa 1
Totale 1375
Città #
Chandler 200
Napoli 103
Millbury 45
Beijing 38
Des Moines 37
Naples 33
Hicksville 32
Nanjing 28
Princeton 27
Lawrence 24
Boston 23
San Mateo 18
Dong Ket 16
Wilmington 15
Ottawa 11
Hebei 10
Houston 10
Nanchang 10
Woodbridge 9
Modica 8
Redwood City 8
Ashburn 7
Caserta 7
Casoria 7
Palma Campania 7
Angri 6
Tianjin 6
Shenyang 5
Ardabil 4
Changsha 4
Fucecchio 4
Jiaxing 4
Leawood 4
Augusta 3
Casagiove 3
Indiana 3
Jacksonville 3
Menlo Park 3
Mumbai 3
Nashville 3
Nürnberg 3
Pizzo 3
Salt Lake City 3
San Giorgio a Cremano 3
Turin 3
Belize City 2
Changchun 2
Dublin 2
Duncan 2
Edegem 2
Fairfield 2
Formia 2
Krefeld 2
La Canada Flintridge 2
Lomazzo 2
Monmouth Junction 2
Pozzuoli 2
Prato 2
Rome 2
Salerno 2
San Marzano sul Sarno 2
Villarosa 2
Battipaglia 1
Bergamo 1
Boardman 1
Caivano 1
Cambridge 1
Casalnuovo 1
Chatsworth 1
Falkenstein 1
Falls Church 1
Ferrara 1
Florence 1
Forlì 1
Fremont 1
Giugliano In Campania 1
Guangzhou 1
Helsinki 1
Jinan 1
Kagoya 1
Kunming 1
La Louvière 1
Legnano 1
London 1
Lviv 1
Marcianise 1
Marigliano 1
Milan 1
Mirabella Eclano 1
Montalbano Jonico 1
Mountain View 1
Mugnano Di Napoli 1
Munich 1
New Delhi 1
New York 1
Nola 1
Norwalk 1
Novi Sad 1
Piedimonte 1
Pomigliano d'Arco 1
Totale 878
Nome #
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors 71
Association of FGFR1 with ERαmaintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer 59
C-Src and EGFR inhibition in molecular cancer therapy: What else can we improve? 51
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers 49
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 48
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 44
Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models 44
1599P - Effects of Hedgehog signaling inhibition on epithelial-stromal interactions in triple negative breast cancer cells 42
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. 37
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status 36
From biology to therapy: Improvements of therapeutic options in Lung cancer 36
Epidermal growth factor receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. 35
Paraneoplastic sensitive neuropathy associated with anti-hu antibodies in a neuroendocrine tumor of duodenum: a case report. 34
Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to anti-epidermal growth factor receptor antibody 33
Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis. 33
Mechanisms of resistance to mTOR inhibitors 32
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 31
Mechanisms of lapatinib resistance in HER2-driven breast cancer 30
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 30
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer 29
Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma. 28
Everolimus induces Met inactivation by disrupting the FKBP12/Met complex 28
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 28
Activating PIK3CA mutations induce an epidermal growth factor receptor (EGFR)/extracellular signal-regulated Kinase (ERK) paracrine signaling axis in basal-like breast cancer 27
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells 26
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2 25
FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer. 25
ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors 24
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 24
Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models 23
A Phase Ib Study of Alpelisib (BYL719), a PI3Ka-Specific Inhibitor, with Letrozole in ERþ/HER2 Metastatic Breast Cancer 23
Use of folfirinox or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: A single institution observational study 23
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. 22
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. 21
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. 21
Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. 21
How can we manage the cardiac toxicity of immune checkpoint inhibitors? 21
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 21
Sphingosine Kinase 1 (SphK1) overespression contributes to cetuximab resistance in human colrectal cancer. 20
Tumor-to-tumor metastasis: breast cancer metastatic to thymic epithelial tumor. 20
Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer 20
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents 20
P0081 Src inhibitors act through different mechanisms to cooperate with EGFR or MEK inhibitors in NSCLC models sensitive or resistant to erlotinib 18
Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies. 17
FGFR1 associates with gene promoters and regulates gene transcription: Implications for endocrine resistance in ER+/FGFR1-amplified breast cancer 16
Treatment of triple-negative breast cancer with TORC1/2 inhibitors sustains a drug-resistant and notch-dependent cancer stem cell population 15
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review 15
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers 13
Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy 12
Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance 12
Predictors of outcomes in patients with EGFR-mutated non-small cell lung cancer receiving EGFR tyrosine kinase inhibitors: A systematic review and meta-analysis 12
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges 11
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer 11
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer 11
Nuclear FGFR1 regulates gene transcription and promotes antiestrogen resistance in ERþ breast cancer 11
FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors 11
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 10
Tumour microenvironment and immune evasion in EGFR addicted NSCLC: Hurdles and possibilities 10
Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC 4
FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER+ Breast Cancer 3
Totale 1553
Categoria #
all - tutte 3119
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3119

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201813 0000 00 00 4306
2018/2019129 00230 176 66 41003
2019/2020253 721918 5913 07 2163521
2020/2021191 3061 1714 136 31274429
2021/2022371 801014 510 411 585584112
2022/2023448 58373026 6875 1458 82000
Totale 1553